{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T13:15:47Z","timestamp":1770470147100,"version":"3.49.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100016136","name":"Fundacion Araucaria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016136","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.lfs.2017.10.028","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:45:49Z","timestamp":1509497149000},"page":"175-179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Addition of vitamin D reverses the decline in GFR following treatment with ACE inhibitors\/angiotensin receptor blockers in patients with chronic kidney disease"],"prefix":"10.1016","volume":"191","author":[{"given":"Abel Esteves","family":"Soares","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Maes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Godeny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andressa Keiko","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e9cio Sabbatini","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taysa Antonia F.","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fl\u00e1vio Henrique M.O.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinicius Daher Alvares","family":"Delfino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2017.10.028_bb0005","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and risks of death: cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2017.10.028_bb0010","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1681\/ASN.2006040377","article-title":"How does proteinuria cause progressive renal damage?","volume":"17","author":"Abbate","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2017.10.028_bb0015","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Chronic Kidney Disease Prognosis Consortium","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2017.10.028_bb0020","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2006121372","article-title":"Renoprotection of optimal antiproteinuric doses (ROAD) study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency","volume":"18","author":"Hou","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2017.10.028_bb0025","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.lfs.2017.10.028_bb0030","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/10408360802165295","article-title":"A growing perspective","volume":"45","author":"Kimball","year":"2008","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2017.10.028_bb0035","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4065\/mcp.2010.0567","article-title":"Vitamin D insufficiency","volume":"86","author":"Thacher","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.lfs.2017.10.028_bb0040","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJMcp1009570","article-title":"Vitamin D insufficiency","volume":"364","author":"Rosen","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.lfs.2017.10.028_bb0045","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1053\/j.jrn.2008.05.004","article-title":"Vitamin D status of chronic kidney disease patients living in a sunny country","volume":"18","author":"Cuppari","year":"2008","journal-title":"J. Ren. Nutr."},{"issue":"1","key":"10.1016\/j.lfs.2017.10.028_bb0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.jrn.2011.02.001","article-title":"Risk factors for hypovitaminosis D in nondialyzed chronic kidney disease patients","volume":"22","author":"Figuiredo-Dias","year":"2012","journal-title":"J. Ren. Nutr."},{"key":"10.1016\/j.lfs.2017.10.028_bb0055","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1053\/j.ajkd.2005.02.029","article-title":"Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in United States","volume":"45","author":"LaClair","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.lfs.2017.10.028_bb0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/j.lfs.2017.10.028_bb0065","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000346789","article-title":"Vitamin D in chronic kidney disease","volume":"180","author":"Li","year":"2013","journal-title":"Contrib. Nephrol."},{"issue":"12","key":"10.1016\/j.lfs.2017.10.028_bb0070","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/archinte.168.12.1340","article-title":"Independent association of low serum 25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality","volume":"168","author":"Dobnig","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.lfs.2017.10.028_bb0075","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/j.1532-5415.2009.02359.x","article-title":"Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults","volume":"57","author":"Ginde","year":"2009","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.lfs.2017.10.028_bb0080","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1530\/EJE-09-1041","article-title":"Low serum 25-hydroxyvitamin D levels are associated with increased all-cause mortality risk in a general population: the Troms\u00f8 study","volume":"162","author":"Hutchinson","year":"2010","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"10.1016\/j.lfs.2017.10.028_bb0085","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.amjcard.2011.09.020","article-title":"Vitamin D deficiency and supplementation and relation to cardiovascular health","volume":"109","author":"Vacek","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.lfs.2017.10.028_bb0090","first-page":"1","article-title":"Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease","year":"2013","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.lfs.2017.10.028_bb0095","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/nep.12052","article-title":"KHA-CARI guideline: early chronic kidney disease: detection, prevention and management","volume":"18","author":"Johnson","year":"2013","journal-title":"Nephrology"},{"key":"10.1016\/j.lfs.2017.10.028_bb0100","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1681\/ASN.2006050520","article-title":"Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy","volume":"17","author":"Tan","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2017.10.028_bb0105","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ndt\/gft360","article-title":"The effect of cholecalciferol for lowering albuminuria in chronic kidney disease: a prospective controlled study","volume":"29","author":"Molina","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"issue":"suppl3","key":"10.1016\/j.lfs.2017.10.028_bb0110","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"Am. J. Kidney Dis."},{"issue":"suppl2","key":"10.1016\/j.lfs.2017.10.028_bb0115","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.lfs.2017.10.028_bb0120","first-page":"11","article-title":"MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine","volume":"155A","author":"Levey","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2017.10.028_bb0125","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.amjhyper.2007.01.017","article-title":"Serun 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey","volume":"20","author":"Scragg","year":"2007","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.lfs.2017.10.028_bb0130","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/ki.2008.501","article-title":"Vitamin D levels and patient outcome in chronic kidney disease","volume":"75","author":"Ravani","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.lfs.2017.10.028_bb0135","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1177\/089686080502500411","article-title":"Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal dialysis patients","volume":"25","author":"Shah","year":"2005","journal-title":"Perit. Dial. Int."},{"key":"10.1016\/j.lfs.2017.10.028_bb0140","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1161\/HYPERTENSIONAHA.109.148619","article-title":"Plasma 25-Hydroxyvitamin D and regulation of the renin-angiotensin system in humans","volume":"55","author":"Forman","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.lfs.2017.10.028_bb0145","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2369-13-55","article-title":"25-hydroxyvitamin D levels and chronic kidney disease in the AusDiab (Australian Diabetes, Obesity and Lifestyle) study","volume":"13","author":"Damasiewicz","year":"2012","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.lfs.2017.10.028_bb0150","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1053\/j.jrn.2010.07.002","article-title":"Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions","volume":"21","author":"Isakova","year":"2011","journal-title":"J. Ren. Nutr."},{"key":"10.1016\/j.lfs.2017.10.028_bb0170","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomized controlled trial","volume":"376","author":"de Zeeuw","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2017.10.028_bb0175","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/HYPERTENSIONAHA.108.113159","article-title":"Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial","volume":"52","author":"Alborzi","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.lfs.2017.10.028_bb0180","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2215\/CJN.03000311","article-title":"Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis","volume":"7","author":"Cheng","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2017.10.028_bb0185","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-2369-13-102","article-title":"Effect of vitamin-D analogue on albuminuria in patients with non-dialysed chronic kidney disease stage 4-5: a retrospective single center study","volume":"13","author":"J\u00f8rgensen","year":"2012","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.lfs.2017.10.028_bb0190","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/MJT.0b013e3182211b3b","article-title":"Treatment of 25-OH vitamin D deficiency in older men with chronic kidney disease stages 3 and 4 is associated with reduction in cardiovascular events","volume":"20","author":"Lishmanov","year":"2013","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.lfs.2017.10.028_bb0195","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/1471-2369-14-199","article-title":"Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies","volume":"14","author":"Zheng","year":"2013","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.lfs.2017.10.028_bb0200","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1253\/circj.CJ-13-0422","article-title":"Serum 1,25-dihydroxyvitamin D and the development of kidney dysfunction in a Japanese Community \u2013 The Hisayama Study","volume":"78","author":"Izumaru","year":"2014","journal-title":"Circ. J."},{"key":"10.1016\/j.lfs.2017.10.028_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/806358","article-title":"Chronic kidney disease influences multiple systems: describing the relationship between oxidative stress, inflammation, kidney damage, and concomitant disease","author":"Tucker","year":"2015","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.lfs.2017.10.028_bb0210","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1681\/ASN.2010111181","article-title":"Estimated GFR, albuminuria, and complications of chronic kidney disease","volume":"22","author":"Inker","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2017.10.028_bb0215","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1681\/ASN.2013030203","article-title":"Active vitamin D treatment for reduction of residual proteinuria: a systematic review","volume":"24","author":"de Borst","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2017.10.028_bb0220","doi-asserted-by":"crossref","unstructured":"James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311(5): 507\u2013520.","DOI":"10.1001\/jama.2013.284427"},{"key":"10.1016\/j.lfs.2017.10.028_bb0225","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ki.2009.175","article-title":"Renoprotective effects of vitamin D analogs","volume":"78","author":"Li","year":"2010","journal-title":"Kidney Int."},{"issue":"41","key":"10.1016\/j.lfs.2017.10.028_bb0230","doi-asserted-by":"crossref","first-page":"15896","DOI":"10.1073\/pnas.0803751105","article-title":"Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc Nat Aca Sci USA (PNAS)"},{"key":"10.1016\/j.lfs.2017.10.028_bb0235","doi-asserted-by":"crossref","first-page":"F791","DOI":"10.1152\/ajprenal.00247.2009","article-title":"Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist","volume":"297","author":"Zhang","year":"2009","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.lfs.2017.10.028_bb0240","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/ki.2010.22","article-title":"Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes","volume":"77","author":"Deb","year":"2010","journal-title":"Kidney Int."},{"key":"10.1016\/j.lfs.2017.10.028_bb0245","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1159\/000320284","article-title":"Effect combination therapy with angiotensin receptor blocker and 1,25-Dihydroxyvitamin D3 in type 2 diabetic nephropathy in KK-AY\/Ta mice","volume":"117","author":"Ohara","year":"2011","journal-title":"Nephron Exp. Nephrol."},{"key":"10.1016\/j.lfs.2017.10.028_bb0250","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1681\/ASN.2006091028","article-title":"Combination therapy with an angiotensin-converting enzyme inhibitor and a Vitamin D analog suppress the progression of renal insufficiency in uremic rats","volume":"18","author":"Mizobuchi","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2017.10.028_bb0255","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1172\/JCI0215219","article-title":"1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the rennin-angiotensin system","volume":"110","author":"Li","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2017.10.028_bb0260","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/ki.2008.408","article-title":"Suppression of renin-angiotensin gene expression in the kidney by paricalcitol","volume":"74","author":"Freundlich","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.lfs.2017.10.028_bb0265","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1681\/ASN.2009080872","article-title":"Vitamin D receptor attenuates renal fibrosis by suppression the renin-angiotensin system","volume":"21","author":"Zhang","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2017.10.028_bb0270","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/1470320312471149","article-title":"Cholecalciferol administration blunts the systemic renin-angiotensin system in essential hypertensives with hypovitaminosis D","volume":"15","author":"Carrara","year":"2014","journal-title":"J. Renin-Angiotensin-Aldosterone Syst."},{"key":"10.1016\/j.lfs.2017.10.028_bb0280","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/ki.2011.224","article-title":"Oral cholecalciferol decreases albuminuria and urinary TGF-\u03b21 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition","volume":"80","author":"Kim","year":"2011","journal-title":"Kidney Int."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320517305428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320517305428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T07:16:58Z","timestamp":1617607018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320517305428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":52,"alternative-id":["S0024320517305428"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2017.10.028","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addition of vitamin D reverses the decline in GFR following treatment with ACE inhibitors\/angiotensin receptor blockers in patients with chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2017.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}